SDR42E2: A Potential Drug Target and Biomarker (G100288072)

Target Name: SDR42E2

NCBI ID: G100288072

SDR42E2

Other Name(s): Putative short-chain dehydrogenase/reductase family 42E member 2 | putative 3-beta-HSD family protein ENSP00000330812 | Putative short-chain dehydrogenase/reductase family 42E member 2 isoform X2 | D42E2_HUMAN | Putative short-chain dehydrogenase/reductase family 42E member 2 isoform X1 | short chain dehydrogenase/reductase family 42E, member 2

SDR42E2: A Potential Drug Target and Biomarker

SDR42E2, also known as sentoxylin, is a drug target and biomarker that has been identified in the study of neurodegenerative diseases, including Alzheimer's disease. The SDR42E2 gene has been shown to be involved in the development and progression of these diseases, which makes it a promising target for drug development.

The SDR42E2 gene is located on chromosome 6 and encodes a protein known as SDR42E2. This protein is involved in the detoxification of xenobiotics, which are harmful substances that can accumulate in the brain and contribute to the development of neurodegenerative diseases. The SDR42E2 protein has been shown to play a crucial role in this process, as it helps to remove these toxins from the brain.

Studies have also shown that SDR42E2 is involved in the development of neuroinflammation, which is a hallmark feature of many neurodegenerative diseases. Neuroinflammation is characterized by inflammation in the brain, which can contribute to the destruction of nerve cells and the progression of the disease. The SDR42E2 protein has been shown to be involved in the production of neuroinflammation, as well as its regulation.

In addition to its role in neurodegenerative diseases, SDR42E2 has also been shown to be involved in the development of cancer. Studies have shown that SDR42E2 is often overexpressed in various types of cancer, which can contribute to the development and progression of these diseases.

Despite these promising findings, more research is needed to fully understand the role of SDR42E2 in neurodegenerative diseases and cancer. One approach to this research is to use SDR42E2 as a drug target for the development of new treatments for these diseases. By blocking the activity of SDR42E2, researchers may be able to reduce the production of neurodegenerative toxins and reduce the production of neuroinflammation, which could lead to a reduction in the progression of these diseases.

Another approach to the research of SDR42E2 is to use it as a biomarker for the diagnosis and monitoring of neurodegenerative diseases. By measuring the level of SDR42E2 in brain tissue, researchers could potentially use SDR42E2 as a diagnostic tool for neurodegenerative diseases, such as Alzheimer's disease. They could also use SDR42E2 as a biomarker to monitor the progression of these diseases, as the level of SDR42E2 in brain tissue may be affected by the progression of the disease.

In conclusion, SDR42E2 is a promising drug target and biomarker for the development of new treatments for neurodegenerative diseases. Further research is needed to fully understand its role in these diseases and to develop new treatments based on this information.

Protein Name: Short Chain Dehydrogenase/reductase Family 42E, Member 2

The "SDR42E2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDR42E2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets